Emergency department–based COVID‐19 vaccination: Where do we stand?
| Autor: | Herbert C. Duber, Richard E. Rothman, Daniel R. Martin, Elissa M. Schechter-Perkins, Phillip Moschella, Michael J. Waxman, Thomas Benzoni |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19) media_common.quotation_subject Population Psychological intervention 03 medical and health sciences Commentary ‐ Unsolicited 0302 clinical medicine Optimism Pandemic Humans Medicine education Pace media_common education.field_of_study SARS-CoV-2 business.industry Vaccination COVID-19 030208 emergency & critical care medicine General Medicine Emergency department Emergency Medicine Emergency Service Hospital business Demography |
| Zdroj: | Academic Emergency Medicine |
| ISSN: | 1553-2712 1069-6563 |
| Popis: | Cautious optimism suggests the COVID-19 pandemic in the United States (U.S.) has reached a turning point. Cases have declined precipitously from their heights in the early winter months and vaccine distribution and administration has moved ahead at an accelerated pace. As of late-March, more than 140 million doses of COVID-19 vaccine had been administered in the U.S., with more than 27% of the population receiving at least one dose.1 Nevertheless, challenges with COVID-19 remain. Rates are increasing in select parts of the country, as non-pharmaceutical interventions such as mask mandates and capacity limits are relaxed; more transmissible variants now represent a greater proportion of new cases; and, vaccine hesitancy persists in many sectors of the population. With this shifting landscape, it is imperative that the U.S. continue to rapidly vaccinate as many individuals as possible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text